Outstanding Third Quarter Results for BillionToOne
BillionToOne, Inc. (NASDAQ: BLLN), a pioneering company in molecular diagnostics, has shared its financial results for the third quarter of 2025. With a commitment to making advanced testing accessible to everyone, BillionToOne has shown real growth in both revenue and operational efficiency.
Remarkable Financial Highlights
This past quarter saw a total revenue of $83.5 million, a significant rise from $38.4 million during the same period in 2024, marking a staggering 117% increase. This growth can largely be attributed to a 52% rise in total tests delivered, alongside a 44% increase in the company's average selling price (ASP).
Explosive Growth in Clinical Testing
Within their clinical testing sector, prenatal testing revenue alone hit $74.1 million, experiencing a robust 102% growth compared to the previous year. Moreover, oncology testing revenue climbed to $8.7 million—a remarkable increase of 7.6 times year-over-year, showcasing a 76% surge quarter-over-quarter as well.
Increased Profitability
Gross profit reached $58.4 million with a gross margin of 70%, an improvement from the 53% recorded in the third quarter of 2024. These impressive figures signify efficiency gains and a focused approach to reducing the cost-per-test while enhancing the pricing structure.
Operational Expenditures
Total operating expenses increased to $48.8 million, reflecting a 49% rise over the previous year. Despite this increase, the operating income shifted to a profit of $9.6 million, a remarkable turnaround from a loss of $12.6 million in the same quarter of the prior year.
Positive Cash Flow and Future Expectations
BillionToOne ended the third quarter with approximately $195.2 million in cash. The company successfully raised $314.0 million from its IPO, which occurred earlier in November 2025. Looking forward, BillionToOne anticipates total revenue for 2025 to fall between $293 million and $299 million, signifying remarkable growth of 93% to 96% year over year.
Webcast and Conference Call Insights
The company hosted a conference call to discuss these results, emphasizing the effectiveness of their innovative technologies and commitment to meeting unmet clinical needs. During the call, Dr. Oguzhan Atay, Co-founder and CEO, reiterated the company's dedication to enhancing their financial profile through rigorous scientific diligence.
About BillionToOne
Headquartered in Menlo Park, California, the organization remains committed to providing cutting-edge molecular diagnostics, using their unique Technology—Quantitative Counting Templates™ (QCT™)—which allows for accurate single-molecule level DNA monitoring.
Frequently Asked Questions
What significant revenue growth did BillionToOne experience?
BillionToOne reported a 117% increase in revenue for the third quarter of 2025 compared to the same period in 2024.
How did the company's gross margin change?
The gross margin increased to 70% in Q3 2025 from 53% in Q3 2024.
What major factors contributed to their revenue growth?
The growth was driven by increased tests delivered and substantial gains in clinical testing revenue, particularly in prenatal and oncology sectors.
What is BillionToOne's financial outlook for 2025?
The firm projects full-year revenue between $293 million and $299 million, indicating significant annual growth.
How has operational income changed year-over-year?
Operational income in Q3 2025 was $9.6 million, a notable recovery from the loss of $12.6 million reported in Q3 2024.
